Clinical Trial Services Market worth $97.41 billion in 2031
The report "Clinical Trial Services Market by Type (Lab, Monitoring, Contracts, Recruitment, PV, Biostatistics), Phase (I, II, III), Therapy (Oncology, Neurology, Dermatology, CVD), Modality (Biologics, Devices), Delivery Model (FSP, Hybrid) - Global forecast to 2031", The global clinical trial services market is expected to reach USD 97.41 billion in 2031 from USD 66.20 billion in 2026, at a CAGR of 8.0% during the forecast period. Factors contributing to growth in the global clinical trial services market include the increasing complexity of Phase I–IV trials, expanding clinical pipelines in oncology, cell & gene therapies, and other specialty therapies, rising pharmaceutical and biopharmaceutical R&D investment, and growing reliance on CROs for outsourced trial execution. In addition, increasing adoption of decentralized and hybrid clinical trials, AI-enabled clinical operations, advanced data analytics, and flexible full-service, FSP, and hybrid outsourcing models is supporting market growth. Regulatory modernization, innovative trial designs, and greater emphasis on patient- and site-centric trial approaches are also creating growth opportunities for clinical trial service providers.
Browse 880 market data Tables and 65 Figures spread through 530 Pages and in-depth TOC on "Clinical Trial Services Market by Type (Lab, Monitoring, Contracts, Recruitment, PV, Biostatistics), Phase (I, II, III), Therapy (Oncology, Neurology, Dermatology, CVD), Modality (Biologics, Devices), Delivery Model (FSP, Hybrid) - Global forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/clinical-trials-market-405.html
By modality, the biologics segment is estimated to register the highest CAGR during the forecast period.
By modality, the clinical trial services market is segmented into small molecules, biologics, biosimilars, and medical devices & IVD devices. The biologics segment is expected to register the highest CAGR during the forecast period. This growth is attributed to the expanding clinical pipeline of monoclonal antibodies, cell & gene therapies, vaccines, recombinant proteins, antibody-drug conjugates, and other complex biologic therapies. These programs generally require specialized patient recruitment, biomarker and bioanalytical testing, intensive safety monitoring, complex site management, cold-chain and clinical supply capabilities, and specialized regulatory expertise, increasing sponsors’ reliance on outsourced clinical trial services.
By delivery model, the hybrid model is estimated to register the highest CAGR during the forecast period.
Based on delivery model, the clinical trial services market is segmented into Full-Service Outsourcing (FSO), Functional Service Provider (FSP), and Hybrid models. The hybrid model is expected to register the highest CAGR during the forecast period. The growing preference of sponsors for outsourcing approaches that combine the end-to-end accountability of FSO with the flexibility, functional control, and scalable resources of FSP arrangements is driving its growth. Hybrid models enable sponsors to retain control over strategically important trial functions.
The Asia Pacific region is expected to register the highest CAGR during the forecast period.
Based on region, the clinical trial services market is segmented into six regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to register the highest growth rate during the forecast period, supported by expanding pharmaceutical and biopharmaceutical R&D activity, increasing Phase I–IV clinical trial activity, improving clinical research infrastructure, and access to large and diverse patient populations.
The clinical trial services market is competitive, with leading CROs and specialized providers pursuing service expansion, technology integration, strategic partnerships, and geographic expansion to strengthen their positions. Prominent players include Thermo Fisher Scientific Inc. (PPD, Inc.), IQVIA Inc., ICON plc, Laboratory Corporation of America Holdings, Syneos Health, WuXi AppTec, Eurofins Scientific, Parexel International Corporation, Fortrea Inc., Medpace, SGS, Frontage Labs, Pharmaron, and Tigermed, among others. These companies compete on global site reach, therapeutic expertise, Phase I–IV execution capabilities, service breadth, data and technology capabilities, and flexible FSO, FSP, and hybrid outsourcing models.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
In addition, MarketsandMarkets Sales Intelligence enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Clinical Trial Services Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
